Cargando…
The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
A loading dose of MPA employing a regimen of 1,000 mg six hourly for 8 doses can achieve plateau levels above 100 ng ml-1 within the first 36 h of treatment, without any untoward toxicity. This raises the possibility of shortening the time to response for this agent. The additional factor of the tim...
Autores principales: | Canney, P. A., Dowsett, M., Priestman, T. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1988
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246490/ https://www.ncbi.nlm.nih.gov/pubmed/2971386 |
Ejemplares similares
-
An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.
por: Johnson, J. R., et al.
Publicado: (1984) -
The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1987) -
Phase II study of high-dose medroxyprogesterone acetate in advanced malignant melanoma.
por: Becher, R., et al.
Publicado: (1989) -
Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate
por: Yuasa-Shibasaki, Erina, et al.
Publicado: (2017) -
Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022)